Bevespi Aerosphere (Glycopyrrolate/Formoterol fumarate) for COPD

Overview
Bevespi Aerosphere is a prescription drug approved by the Food and Drug Administration (FDA) as long-term maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere is a combination drug composed of Glycopyrrolate and Formoterol fumarate.

Glycopyrrolate is an anticholinergic. Formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA). Both drugs are bronchodilators. Both drugs are believed to work by relaxing and dilating the airways, making it easier to breathe.

How do I take it?
Bevespi Aerosphere is taken twice daily.

Bevespi Aerosphere comes as an inhaler.

Side effects
The FDA-approved label for Bevespi Aerosphere lists common side effects including cough and urinary tract infections.

Rare but serious side effects listed for Bevespi Aerosphere can include paradoxical bronchospasm (bronchospasm caused by taking medication), and worsening narrow-angle glaucoma or urinary retention.

For more details about this treatment, visit:

Bevespi.com – AstraZeneca
https://www.bevespi.com/